Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS70MP
|
|||
| Drug Name |
DM199
|
|||
| Drug Type |
Recombinant?protein
|
|||
| Indication | Cerebral ischemia [ICD-11: 8B11; ICD-10: I67.8] | Phase 2 | [1] | |
| Ischemic stroke [ICD-11: 8B11.5Z; ICD-9: 434.91] | Phase 2 | [2], [3] | ||
| Autoimmune diabetes [ICD-11: 5A10] | Phase 1/2 | [4] | ||
| Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 1/2 | [5] | ||
| Company |
DiaMedica Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04123613) Multiple Doses of DM199 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT01845064) A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients. U.S. National Institutes of Health. | |||
| REF 5 | ClinicalTrials.gov (NCT01845064) A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients. U.S. National Institutes of Health. | |||
| REF 6 | Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.